IPIX Innovation Pharmaceuticals Inc | Keep reading me on IHub. Use your i (1) | 06/29/2017 7:18:15 PM |
IPIX Innovation Pharmaceuticals Inc | "We all know" . . . Most of the pos (2) | 06/29/2017 4:28:52 PM |
IPIX Innovation Pharmaceuticals Inc | Do you actually read the post. I st (3) | 06/29/2017 4:00:50 PM |
IPIX Innovation Pharmaceuticals Inc | If you are directing your post to m (2) | 06/29/2017 3:43:54 PM |
IPIX Innovation Pharmaceuticals Inc | Never on IHub. Read it once years a | 06/29/2017 2:31:53 PM |
IPIX Innovation Pharmaceuticals Inc | Please revisit my last post as I cl (2) | 06/29/2017 1:48:43 PM |
IPIX Innovation Pharmaceuticals Inc | The trials they are pursuing first (2) | 06/29/2017 1:23:05 PM |
IPIX Innovation Pharmaceuticals Inc | This is great. You are criticizing (2) | 06/29/2017 12:38:32 PM |
IPIX Innovation Pharmaceuticals Inc | It appears their cash flow burn rat (2) | 06/29/2017 10:35:05 AM |
IPIX Innovation Pharmaceuticals Inc | Trying to be objective, acknowledgi (4) | 06/28/2017 8:31:25 PM |
IPIX Innovation Pharmaceuticals Inc | As a speculative bio play, this is (2) | 06/28/2017 2:55:46 PM |
IPIX Innovation Pharmaceuticals Inc | Do not disagree. My point is that t | 06/19/2017 8:12:38 PM |
IPIX Innovation Pharmaceuticals Inc | Note that Baxdela was approved by t | 06/19/2017 5:04:00 PM |
IPIX Innovation Pharmaceuticals Inc | B-OM is the likelier candidate for | 05/31/2017 12:55:19 PM |
IPIX Innovation Pharmaceuticals Inc | Exactly. If Leo et. al. went with a (1) | 03/24/2017 11:18:17 AM |
IPIX Innovation Pharmaceuticals Inc | If you are referring to the OM tria (4) | 03/24/2017 9:35:35 AM |